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Henry Ford Hospital Clinicopathological Conference
Metamorphosis in chronic granulocytic leukemia in a 60-year-old man
Participants:
Protocol:

Dr. Ellis J. Van Slyck, D e p a r t m e n t o f Internal M e d i c i n e , D i v i s i o n of H e m a t o l o g y

Discussant:

Dr. Robert K. N i x o n , D e p a r t m e n t of Internal M e d i c i n e , Second M e d i c a l D i v i s i o n

Radiology:

Dr. M a r k C . W e i n g a r d e n , D e p a r t m e n t of Diagnostic Radiology

Pathology:

Dr. John W . Rebuck, D e p a r t m e n t o f Pathology, D i v i s i o n of H e m a t o l o g y

Case Presentation

As an outpatient, his myleran dosage was gradually tapered as the
blood counts responded. On February 27, the white count was
40,000 and the platelet count 400,000. On May 10, the white
count was 21,000, hemoglobin 13.6% gm, and the platelet count
717,500. In July 1976, the white count was 28,400, hemoglobin
13.8 gm%, and platelet count 620,000. In August, 1976, the
patient was noted to have a white count of 62,000 and a platelet
count of 1.2 million. The spleen, although smaller, was easily
palpable.

This 60-year-old white man came to Henry Ford Hospital in
December 1975, complaining of increased fatigability over the
preceding year. He had also noted mid-abdominal soreness after
lifting. His own physician found that his spleen was grossly
enlarged and that he had a high white blood count. His past
history included a partial gastrectomy for an ulcer in 1960 and a
stroke in 1972 with no residual. He was said to be diabetic since
1973 and had been taking 12 units of insulin.

The patient was not seen again until June 1977, having been
followed by his local doctor. At this time he reported that he had
been hospitalized on several occasions for Gl bleeding and that xrays had demonstrated gastric and duodenal ulcerations. He had
continued to take myleran more or less on a continuous basis. A
dull, constant aching in the upper quadrant, weight loss, progressive fatigue and some ankle edema had prompted his return to
Henry Ford Hospital. On June 16,1977, his physical examination
showed a blood pressure of 130/88. The pulse was 88 and regular.
Pertinent findings were generalized hyperpigmentation, bilateral
basilar rales, an unremarkable cardiac auscultation, a soft abdomen with splenomegaly 3-4 finger breadths below the level of the
umbilicus. There was a small amount of pedal edema. The
hemoglobin was 19.4 gm% and white count 78,300. The findings
of hyperpigmentation and rales raise the question of interstitial
pulmonary changes related to myleran therapy.

On admission, the pertinent physical findings were blood pressure 142/78, pulse 80 and regular. He was in no distress and
mildly obese. There was no lymphadenopathy. Abdominal exam
revealed a liver span of 10 cm. The spleen was markedly enlarged,
measuring 16 cm below the left costal margin with a total span of
24 cm.
Initial laboratory values revealed a hemoglobin of 10.2 gms, white
count 263,000/cu ml. The peripheral smear showed moderate
polychromasia of RBCs. The WBC differential was as follows:
segmented neutrophils 36%, bands 25%, metamyelocytes 6%,
myelocytes 1 2 % , early myelocytes 6%, myeloblasts 1 % ,
eosinophils 5% (3 immature), basophils 7% (immature). Philadelphia chromosome was present. LAP was 0. The platelet count
was 637,000/cu ml. Reticulocyte count was 1.2%. Uric acid was
8.7 mg/dl. The LDH was greater than 700 units and the triglyceride was 345 mg/dl. BUN, creatinine, electrolytes, and
alkaline phosphatase values were normal. The VDRL was nonreactive. The PT and PTT were within normal limits. Urinalysis
was normal. Vitamin B12 level was 7,616 pg/dl. Serum folic acid
was 4.9 ng/dl. The bone marrow aspiration and biopsy were
consistent with a diagnosis of chronic granulocytic leukemia
(CCL). X-ray o f t h e chest showed no acute process. The EKC was
considered normal.

After therapy with Rubidazone was started, the white count
responded from 78,000 to 4,700. Hemoglobin at this point was
8.4 gm%, and the platelet count was 195,000. On September 6,
he had completed three courses of Rubidazone. His blood count
was hemoglobin 7.4 gm%, white count 9,900. The nature of the
blood and marrow differentials at this time changed dramatically
and will be the subject of the discussion and slide presentation.
The patient's course was downhill over the next two to three
months with weakness, fever, diffuse bone aching, further enlargement of the liver and spleen, more edema, bilateral calf
tenderness, further progression o f t h e anemia, and, subsequently,
another marked increase in the white cells to over 200,000.

The patient was placed on myleran and responded appropriately
with a satisfactory reduction of his white cell count, restitution of
his hemoglobin, and diminution of his spleen size.
He continued this treatment until he was discharged on December 23, at which time the dose was reduced to 2 mgs three times
a day. W h i l e in the hospital, his insulin was d i s c o n t i n u e d .
The patient was instructed in a diabetic diet and also given
allopurinol.

The patient returned on September 30, weak, febrile, and aching
in most of his bones. His temperature was 39.8, blood pressure
85/60, and pulse rate was 92. His skin was dry and hot. Marked
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hepatosplenomegaly was noted. There was 2 4- edema of the
lower extremities and bilateral calf tenderness. There were a few
basilar rales. The neck was supple. Pertinent laboratory data
included a hemoglobin of 6.8 gm%, and a white count of
280,000. The many bizarre forms in the peripheral blood precluded an accurate platelet count.
The patient died on October 3, after he failed to respond to
appropriate antibiotics forthe consolidated right upper lobe seen
on x-ray Sputum culture had shown moderate E. coli.
Our task is to try to define the possible complications this patient
experienced as a result of his chronic granulocytic leukemia.

Radiology Findings
Dr. Weingarden:
When the patient's first x-ray film (Fig. 1) was taken on
December 15, the day after admission, we found no significant abnormalities. This film shows some blunting at the
right costophrenic angle, probably due to pleural thickening, but no acute process was seen at this time. Six months
later, on June 16, 1977, he was examined again (Fig. 2).
Bilateral densities involving the lung fields diffusely were
noted, as well as a reticular nodular pattern of an interstitial
nature. Dr. Nixon mentioned the possibility that the patient
had myleran toxicity, and this is also possible from looking
at this film. By the time of the patient's death on October 3,
the consolidative changes in the right upper lobe had
increased, although the left lung still seemed not to be
involved (Fig. 3). The most likely radiographic diagnosis at
this point would be a pneumonitis with some atelectasis of
the right upper lobe. Also, the trachea may be shifted
slightly to the right.

Fig. 1

Clinical Discussion
Dr. Nixon:
Our knowledge of the evolution of chronic granulocytic
leukemia (CGL) has been greatly enhanced by the study of
atomic bomb casualties at the University of Hiroshima. In
the earliest proliferative phase, after the presence of a
Philadelphia chromosome has been initially ascertained,
there is approximately a 6.3 year proliferative period to the
point where we can first discern a hematologic change at
about a 10,000 white cell count, accompanied by the
appearance of basophilia, increase in platelets, and a
decrease in leukocyte alkaline phosphatase. At approximately 20,000 white cell count, immature granulocytes,
less than 5%, begin to appear, and at a white cell count of
25,000, an increase in serum vitamin B12 is detectable.
When the white blood cells increase to between 50,000
and 100,000, the clinical features, including splenomegaly,
make the diagnosis evident.

Fig. 2

This patient responded satisfactorily to myleran therapy for
five to six months and then underwent a decided change.
Over the next three to four months, in spite of a change of
chemotherapy, he continued to decline and died with a
terminal infection.
What are the possible things that may happen to a patient
with chronic granulocytic leukemia and that would seem
to pertain best to the patient under discussion? Myelosuppression and a lethal outcome from chemotherapy may
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certainly of interest. Since the symptom expressions of
histamine release in basophilic leukemia are not as profound as one encounters with a mast cell origin of histamine release, we may not have the other features that
characterize systemic mastocytosis, such as a characteristic
flush or other marked symptoms of hyperhistaminemia.
The terminal event of a pneumonia that did not respond to
antibiotics would be consistent with this man's disease. In
the evolution of chronic granulocytic leukemia, functional
changes in granulocytes presumably occur, as suggested by
alterations in their phagocytic indices and bactericidal
capacity; these, in turn, may make the patient more susceptible to infection.
Student Diagnosis:
The medical students feel that the early clinical course is
consistent with the diagnosis of CGL except for three
observations: 1) the duration o f t h e disease was less than
two years; 2) the elevated platelet count did not decrease
with treatment comparable to the decrease in the patient's
white count; and 3) the peripheral smear later in the
patient's course had a number of bizarre forms which
precluded an accurate platelet count. We feel that the
hyperpigmentation and the bilateral basilar rales were
probably secondary to the myleran therapy. We feel that
the platelets are an abnormal and significant part of the
picture, first, because of their increased number. Also, the
thrombotic and hemorrhagic episodes of the patient's
edema, the possible stomach infarct, and the bleeding from
the ulcer all suggest abnormal platelet function, as do the
bizarre platelet forms. Medical students here suspect that
the patient has a megakaryocytic blast transformation of
chronic granulocytic leukemia, which is an unusual condition occasionally seen as the terminal event in chronic
granulocytic leukemia.

Fig. 3

occur. There may be a transition to myelofibrosis, or nonassociated diseases may prevail, particularly those common to middle life, and these may be responsible for death
before the final evolution of the leukemia. Most CGL
patients (in the range of 70%) move into what is termed an
accelerated phase, which terminates in a blast crisis. This
transition is characterized by increasing anemia, increased
leukocytosis, or cytopenia. Our patient, with increased
fatigue, fever, bone pain, as well as further hematologic
change occurring some five to six months after initial
treatment w i t h m y l e r a n , gave evidence that the basic
course of his disease had markedly altered in a way compatible with the accelerated phase that precedes a blast
crisis. In recent years, we have become aware that just as
the Philadelphia chromosome involves not only granulocytes but erythroid elements, megakaryocytes, monocytes and lymphocytes, so the blast transformation that
inevitably occurs in practically all CGL patients may actually involve any ofthese cell lines. Recognition of a terminal lymphoblastic change is clinically important because it
demands a change in therapy, which may, for a period, be
more effective. Measurement of a terminal transferase (deoxynucleotidyl transferase), a DNA polymerase, facilitates
the diagnosis of this lymphoblastic type of crisis.

Questions
Are you making any educated guesses about the nature of
this pneumonitis? Is it some unusual type of infection?
What etiology do you suspect?
Dr. Nixon:
I think it is probably an ordinary bacterial pneumonia. I
don't think we need to suspect some unusual organism,
which certainly may occur in a variety of hemopoietic
diseases and especially with immunosuppressive therapy. I
am willing to accept, at this stage of the man's disease, an
ordinary bacterial process which didn't respond to antibiotics primarily because the patient had no defenses left to
respond with.

At this point comments are in order about the unusual
multiple duodenal and gastric ulcerations which occurred
in our patient when his course was changing hematological ly. These alterations may have been a response to a
marked histamine stimulus supplied by a basophilia which
may accompany a blast crisis. Whether, in turn, this increase in basophils was great enough to qualify for the
diagnosis of basophilic leukemia would be speculative, but
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In regard to the duration o f t h e disease mentioned by the
students, I would answer that from the time of diagnosis to
the culmination o f t h e blast crisis the period is generally
one to four years.

chromatin patterns, the so-called Pelgeroid appearance. In
the leukocyte count, 2 megakaryocytic nuclei were encountered per 100 leukocytes, and 1 polychromatophilic
normoblast per 100 leukocytes. The mature erythrocytes
showed anisocytosis, target cells, burr cells, poikilocytosis,
polychromasia, basophilic stippling, blister cells, and rare
spherocytes. An occasional platelet was a giant monster in
size and appearance, i.e., greater than 8 f i m in diameter.
Larger than normal platelets are often found as a sign of
increased rates of platelet production, but the monster
forms that appeared here are found o n l y in the myeloproliferative syndromes, both in chronic granulocytic
leukemia as well as in agnogenic myeloid metaplasia.
Indeed, increased basophilic granulocytes may be found in
both CGL and agnogenic myeloid metaplasia. However,
such greatly increased numbers and degree of basophil
immaturity as found in this patient are a feature only of
granulocytic leukemia and its basophilic variants to be
discussed below.

Pathology Discussion
Dr. Rebuck:
I would like to add a point about the duration of chronic
granulocytic leukemia. We should now consider t w o
courses in a disease process: first, the natural evolution of
the disease before treatment becomes available, and then,
the course of the disease as modified by treatment. Previously, with radiotherapy alone, the median survival of a
patient with CGL was 3.1 years. I believe the latest SWOG
figu res with chemotherapy have a median survival just
under that figure. Lest you think there has been no progress,
the life quality of such patients has greatly improved, even
though we have not increased their survival time.
Well, Dr. Nixon, thank you for focusing on the real problem in this case, namely, the sudden change in the nature of
our patient's course in June 1977. I liked your term the
"accelerated phase". The term "-blast crisis" generally
used in the U.S. to refer to such acceleration of the course
of chronic granulocytic leukemia is not nearly as accurate.
Gunz' standard text on the leukemias (1) prefers the term
"metamorphosis." The reason I like "acceleration" or
" m e t a m o r p h o s i s " is that in CGL not all the dramatic
changes are conversions to a -blast crisis, although I am
glad you mentioned a most important conversion recently
recognized, that of a truly lymphoblastic crisis, proved by
demonstrating lymphoblastic surface markers on the -blasts
of some cases. You also mentioned the common myeloblastic crisis or the conversion to an acute myelomonocytic leukemia and, rarely, to an acute erythroblastic
leukemia or acute megakaryocytic leukemia, as mentioned
in the students' diagnosis.

When Paul Ehrlich was a medical student, he used the
aniline dyes to discover the tissue mast cell and the peculiar property of the mast cell granule to change the dye
color, a property he termed "metachromasia". This was in
1877. Fourteen years later, long after delineating the neutrophilic, eosinophilic and normoblastic and megaloblastic
series we know today, he worked out the basophilic granulocytic development in a case of CGL. The basophilic
series developed in a fashion parallel to the previously
described neutrophilic and eosinophilic series and was
similarly derived from the marrow stem cells. The first
member of the series he named " b a s o p h i l i c promyelocyte," for the member with the first appearance of
m e t a c h r o m a t i c a l l y staining specific granules. The
mitotically dividing offspring he designated "basophilic
myelocytes," which transformed in turn without further
cell division to the "basophilic metamyelocyte," with its
broadly indented nucleus, and to the end-stage, mature
"basophilic granulocyte" with its poorly segmented, but
irregularly lobulated nucleus.

The nature o f o u r patient's acceleration in June 1977 was
none of the aforementioned, as study of his blood smear
and bone marrow at the time indicated. Examination ofthe
peripheral blood smear revealed a leukocytic differential
count as follows: myeloblasts 8.5%; progranulocytes
4.0%; neutrophilic promyelocytes 0.5%; neutrophilic myelocytes 3.0%; neutrophilic metamyelocytes 2.0%; bands
3.0%; segmented neutrophils 21.5%; eosinophilic promyelocytes 0 . 5 % ; e o s i n o p h i l i c myelocytes 3 . 5 % ;
eosinophilic metamyelocytes 1.0%; eosinophils 3.0%; immature basophils 15.5% (Fig. 5); basophilic granulocytes
26.0% (Fig. 4); lymphocytes 7.5%; and monocytes 0.5%.
Some of the neutrophilic myelocytes had coarse, dark

Had we performed the differential only on the predominant
basophilic granulocytic series, the basophilic leukocytic
differential revealed basophilic promyelocytes 5 % ;
basophilic myelocytes 14%; basophilic metamyelocytes
11%; and basophilic leukocytes 70%. Amid the 5% immature eosinophils in the general differential, we ran across
some of the eosinophilic promyelocytes and myelocytes
which contained large, refractile, globular, second set lysosomes with both eosinophilic staining in some areas of the
cell body intermingled with basophilic staining, similarly
structured granules. Ehrlich noted such eosinophilic granulation and correctly gave no great significance in cell
identification to such members of the eosinophilic series.
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basophilic conversion of CGL alter the prognosis of the
disease? Is basophilic conversion a form of "-blast" crisis?
Does basophilic conversion require achange in therapy? Is
there an acute basophilic leukemia as well as a basophilic
conversion of CGL? Finally, does basophilic leukemia differ
from tissue mast cell leukemia?

From time to time, they are misinterpreted as signifying a
leukemic change per se, which they do not.
From the examination of the peripheral blood slide we
diagnosed a "basophilic leukemic conversion" of CGL and
not exactly a " - b l a s t c r i s i s , " as had been expected
clinically. After all, the granulocytic stem cells comprised
only 13.5% in the blood slide. To support our interpretation
ofthe peripheral blood, we next examined the bone marrow aspirate at this time. This revealed myeloblasts 13.0%;
progran ulocytes 4.0%; neutrophilic promyelocytes 3.4%;
n e u t r o p h i l i c myelocytes 0 . 4 % ; n e u t r o p h i l i c metamyelocytes 2.2%; bands 0.6%; segmented neutrophils
13.6%; eosinophilic promyelocytes 2.2%; eosinophilic
myelocytes 1.8%; eosinophilic metamyelocytes 1.2%;
eosinophils 4.8%; immature basophils 14.6%; basophilic
granulocytes 28% (Figs. 4 and 5); lymphocytes 6.2%;
monocytes 0.2%; megakaryoblasts 2.4%; polychromatophilic normoblasts 0.8%; orthochromatic normoblasts
0.4%; normoblastic mitoses 0.2%. Some ofthe myeloblasts
were micromyeloblasts supporting the leukemic nature of
the process. Putting the marrow findings together with
those from the blood slide, we made a diagnosis of "subacute basophilic leukemia" complicating CGL, which Dr.
Nixon discussed as one possibility. An earlier biopsy o f t h e
patient's marrow in April 1977, which had been obtained
elsewhere, was made available to us, and a surprising
fibrosis of the entire marrow spaces, highlighted only by
the presence of entrapped megakaryocytes, intervened at
that time. The intervention of marrow fibrosis in a known
case of CGL often signifies a severe prognosis, as in this
case.

Let us consider the last problem first. In spite of Ehrlich's
clear distinction between the "tissue mast cell" with its
round, lymphocyte-like nucleus and huge cell body (15 to
30/Am in diameter) and the small basophilic granulocyte of
the blood and its marrow precursors, the two cell lines
were often lumped together for many years. The fact that
both cells contain similar functional constituents (histamine, heparin and a potent chymase, and serotonin in
animals) enhanced this tendency. But, properly, they
should be separated into dual tissue and blood-borne roles,
just as we recognize both tissue macrophages and those
arisingfrom migrated mononuclears from the blood. In the
basophilic granulocytic leukemias, distinction from systemic mastocytosis and its leukemic counterpart, tissue
mast cell leukemia, was never a problem because of the
excellent distinction Efrati and his colleagues made in their
original description of the tissue mast cell diseases. Although tissue mast cell leukemia (Fig. 6) is rarely confused
with the basophilic variant of CGL, it is confused, surprisingly enough, with the more common promyelocytic or
progranulocytic variant of acute granulocytic leukemia
marked by the coarse and numerous azurophil granules
(first set lysosomes) in the cytoplasm of the progran ulocytes
and promyelocytes. The excessive bleeding that may be a
symptom in both tissue mast cell leukemia (on the basis of
focal hyperheparinemia) and in the promyelocytic leukemic syndrome (on the basis of gran uie-ind ueed consumptive coagulopathy) often confuses the distinction. Furthermore, the high heparin content o f t h e leukemic tissue
mast cell may lead to needle-like, crystalline precipitates
which are then mistaken as "Auer" rods. Another point of
confusion is the conversion of the small, round, lymphocyte-like nuclear chromatin pattem of the normal tissue
mast cell to the blast-like, finely stippled, chromatin pattern
of the leukemic tissue mast cell.

As stated above, Ehrlich himself, as early as 1891, had
noted moderate but significant increases in basophilic
granulocytes in CGL. In 1906 Joachim (3) was the first to
report a variant of CGL such as we see in our study with
extreme basophilia. From that time on, sporadic cases of
CGL (3-9) with extreme elevation in the basophilic leukocyte count have been reported with the designation of
"basophilic leukemia." Forkner, in his 1938 pioneer text on
leukemia (3), included a chapter on basophilic leukemia
and was able to cite 11 cases in this category. Forkner (3)
suggested that "many if not all of the cases recorded of
basophilic leukemia in man may represent merely an exaggeration o f t h e basophilia seen not infrequently in patients
with straightforward chronic myelogenous leukemia particularly subsequent to treatment." This early view has
been confirmed in most respects by more recent reviews
(1).

All ofthis confusion could be settled easily, inexpensively,
and promptly by applying toluidine blue staining with
a l c o h o l i c fixation of the marrow or peripheral blood
smears to be questioned (Figs. 5 and 7). Modern cytochemists agree with our earlier observations that alcoholic
toluidine blue induces a metachromatic (purple) staining of
both tissue mast cell and basophilic granulocytic granules
but does not do so to the azurophilic granules of the
progran ulocytes and neutrophilic promyelocytes with
which they may be confused in Romanowski stains. However, the skilled morphologists (and here we must include

Why, then, our conference case? First of all, one can verify
the existence of the various stages of basophilic granulocytic development that Ehrlich described. Beyond that, a
number of considerations justify further study. Does the
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the many hematology specialists among our medical technologists) have an even simpler way of distinguishing between metachromatic granules and the a z u r o p h i l i c
lysosomes in ordinary blood or marrow smears. Since the
high water content of the Romanowski stains dissolves the
metachromatic granular contents in a helpful but haphazard fashion, the metachromatic granules will vary from
solid purple to those which are washed out centrally or
peripherally with a smudge of pink remaining in their
centers or surrounding the granules, to those granules in
which the contents are completely dissolved away, with
their former sites marked by an empty cytoplasmic vacuole. In contrast, because the azurophilic granules are a
hardy lot, they retain their uniform purple stain even in
their damaged presentations in the smear.

mias and significantly depressed levels in the acute promyelocytic syndrome.
Another question we raised earlier concerns a change in
the prognosis of CGL if the transformation to basophilic
leukemia is established. In general, the answer is that the
prognosis is worse than average. Gunz and Baikie (1) in
their exhaustive leukemia text speculate that the reason
may be that it is often detected at what they term "the stage
of (leukemic) metamorphosis." Thus, the transformation to
basophilic leukemia encountered in this study should also
be included in the -blast crises described for CGL. The one
k n o w n exception to this generalization is cited by
Wintrobe in the latest edition of his text (14). He described
a patient with 80.0 x 10'/L basophils who received busulfan therapy and lived 87 months after the diagnosis had
been made. Wintrobe's patient brings us to the final question we asked: Should there be a change in therapy for
patients such as the one we are studying? As in all chemotherapeutic trials, the appropriate answers cannot be
given until the existence of this change in chronic granulocytic leukemia is widely recognized.

Next, is there an acute basophilic granulocytic leukemia
either arising de novo or as a so-called "-blast" crisis of
CGL? Hule (11) reported two cases of acute granulocytic
leukemia with predominant basophilic granulocytes and
Peralta and his associates (12), in the Cuban literature,
confirmed the existence of acute basophilic leukemia. In
these cases, two problems arise. First, unfamiliarity with the
morphology of basophilic promyelocytes may lead to their
misdiagnosis as progranulocytes or neutrophilic promyelocytes. Second, failure to employ an alcoholic toluidine
blue staining procedure to weed out the acute basophilic
granulocytic leukemias from what appears to be an acute
myeloblastic leukemia in Romanowki stains appears the
most valid criticism o f t h e French American British (FAB)
classification of the acute leukemias. The few cases of
acute basophilic leukemia 1 have studied did not respond
to therapy considered appropriate for AGL and had an
unremitting course. Further study will eventually determine
if acute basophilic leukemias should have the same grave
prognoses as the acute T-lymphoblastic and B-immunoblastic leukemias currently in the acute lymphocytic
leukemia series.

To understand better the possibly pathophysiological consequences of neoplasia of this series, we should know
some of the more important properties and functions ofthe
basophilic granulocyte (15):
1. Locomotion
2. Chemotaxis (16)
a. Lymphocyte dependent
b. Lymphocyte independent
3. Phagocytosis
a. For RBC
b. As host LE cell
4. IgE receptors (appropriate allergen leads to degranulation and/or disruption ofthe entire basophil,
when complexed to IgE.)
5. Heparin content in granules (metachromatic acid
mucopolysaccharide)
a. May lead to local hemorrhage due to heparin
excess
b. Stimulates fibroblasts to increased collagen formation (fibrosis)
6. Chymase content (may lead to local tissue necrosis)
7. Histamine content (complement-induced release)
8. Serotonin content in laboratory animal basophils
(not proved for human basophils)
9. Basophil hypersensitivity reaction (as in ulcerative
colitis, Hunner's ulcer, penicillin sensitivity, histoincompatibility, etc)
10. Platelet-activating factor derived from IgE sensitized
basophils causing platelet function

Lest anyone think these remarks are too provincial, at the
International Congress of Hematology in Brazil in 1972 the
Italian workers (13) reported 37 cases of acute basophilic
leukemia in a 15-year period at the Cardarelli Hospital in
Naples. Quattrin stated: "The scant number of reported
cases of acute basophilic leukemia does not correspond to
reality, the main reasons being: (a) the non-performance of
the specific toluidine blue or Astra blau stains, on account
of which many cases of acute granular leukemia are classified as common myeloblastic leukemia; (b) the very fast
fatal course of the disease." He felt that a great many cases
attributed to acute promyelocytic leukemia belonged instead to acute basophilic leukemia. According to Quattrin,
it is important in diagnosing these cases to distinguish
between normal fibrinogen levels in the basophilic leuke-
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11. Kallikrein-like activity (compensatory basophilic
migration in lesions of patients with Fitzgerald factor deficiency)

CGL had been diagnosed. Important findings in the patient's last marrow report were 32.2% myeloblasts, 1 7.0%
immature basophils, and 18.6% mature basophilic granulocytes. Extensive leukemic infiltration was found in the
liver (3,190 gm) and spleen (1,960 gm), as well as in the
mesenteric and para-aortic nodes and kidneys. Terminally,
the marrow showed 90-100% infiltration of both the myeloblasts and the basophilic granulocytes that had marked
his later course, combined with extensive fibrosis, as previously noted.

Pertinent to a study of this basophilic cell line is the recent
report by Juhlin and his colleagues (17) of the case of a
52-year-old patient w h o , instead of having too many
basophils, constantly lacked both eosinophil and basophilic granulocytes. The patient suffered from repeated
infections, asthma, and hemolytic anemia. Juhlin et al
argued that the lack was due to immunologic destruction of
the missing cells. Because of the combined defect with its
immunologic etiology, we still do not know what life would
be like without basophils alone, but their case affords
important clues.

Dr. Van Slyck:
As part of a CGL treatment protocol, those of us involved in
Southwest Oncology Group (SWOG) investigations looked
atthe fibrosis in marrows before, during, and after myleran
therapy, with the idea of trying to obtain useful information
on this issue. The study took ten years to complete because
of very slow case accrual, and the results were inconclusive. Many ofthe 100 patients in the study clearly had some
fibrosis in their marrows before they were ever treated. The
disease itself, as Dr. Rebuck stressed, was associated with
an increase in marrow fibrosis as time passed, but how
much of a contribution myleran therapy made to the
process is speculative. We all suspect that it does something to accelerate fibrosis, but individual cases differ.
Thus, we have no clear causal relationship concerning the
marrow fibrosis in today's case. So, in summary, we believe
that myleran can enhance marrow fibrosis, but the fibrosis
can also proceed without myleran.

Many years ago, Henry Rappaport reported that the increased reticulin deposition and fibrosis o f t h e bone marrow in chronic granulocytic leukemia were in direct proportion to the absolute basophilic granulocyte count of the
marrow. Significantly, the marrow of our patient showed
pronounced fibrosis at the time of the "basophilic granulocytic crisis," a fibrosis which became more severe as
death approached. Another reason for embarrassment of
the microcirculation of the marrow leading to marrow
fibrosis is that as greatly increased numbers of megakaryocytes become activated, a cocoon of fibrin (then
reticulin) forms around those that have broken out into
marrow sinuses, resulting in the classic "entrapped megakaryocytes" of the myeloproliferative disorders. Furthermore, I believe that any marked hyperplasia of cellular
elements of any type in the confined marrow cavity leads
to some impingement upon the thin-walled marrow sinus
microcirculation, with the same resulting fibrosis. Obviously, all these mechanisms were present and potentially
operative in our patient. The presence of the Philadelphia
chromosome and zero LAP score in this patient on his
initial admission in December 1975, along with the original, extremely high white count, confirmed the basic diagnosis of chronic granulocytic leukemia. Fibrosis of the
marrow has occasionally been reported in CGL and is
being reported more and more frequently as another grave
prognostic sign in this disease.
The remainder of the patient's course was as follows. After
a third course of Rubidazone therapy, which initially reduced his peripheral white count, his white cell and platelet counts began to rise again in late August without
significant reduction in the tumor in his liver and spleen.
Hydroxyurea therapy was started, but his leukocytes continued to climb to 180,000 cu mm with 28% mature and
immature basophils persisting and an increase in myeloblasts to 21 % ofthe total leukocytes. Death was due to a
rapdily developing E. coli pneumonia, as Dr. Nixon indicated, on October 4, 1977, approximately 22 months after

43

Van Slyck, Nixon, Weingarden, and Rebuck

Fig. 4
Basophilic Leukemia Complicating Chronic Granulocytic Leukemia
This photomicrograph represents the patient's blood and marrow picture in June 1977 (mature basophils in the blood 2 6 % ; immature basophils 15.5%).
The three central cells are mature basophilic granuk>cytes. This picture should be compared w i t h the morphology of the tissue mast cells in Fig. 6.
Leishman's stain ( x 1700).

Fig. 5
Deeper Leishman staining on the left (ordinary Romanowski blood staining) of the basophilic promyelocytes contrasted w i t h the identifying paler but
definitely metachromatically positive basophilic promyelocyte counterpart in the alcoholic toluidine blue stain on the right. Such metachromatic
identification is essential to avoid misinterpretation of the basophilic promyelocyte in ordinary blood stains as a "heavy granular promyelocyte" of the
neutrophilic series ( x 1700).
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Fig. 6
Tissue Mast Cell Leukemia
Representative field from the blood or marrow of a patient with tissue mast cell leukemia so that the morphology of the leukemic tissue mast cells can be
compared with the structure of the leukemic basophilic granulocytes in Figs. 4 and 5. Note the larger cytoplasmic-to-nuclear ratk) in tissue mast cells,
and the tear-drop secretion of heparin at the edge. Like basophil granules, tissue mast cell granules contain heparin and are truly metachromatic
Leishman's stain (x 1700).

r

Fig. 7
Alcoholic toluidine blue staining of leukemic tissue mast cells from the same patient depicted in Fig. 6. Note the metachromatic (purple) staining of the
granules. The large cell body of the leukemic mast cells can be appreciated here when contrasted with the smaller cytoplasmic rim presented by the
basophilic promyelocytes of Fig. 5. Tissue mast cell leukemia is another leukemia that can be misinterpreted as "promyelocyte" leukemia when
metachromatic staining is not employed. Alcoholic tolukline blue stain (x 1700).
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